Intervacc Rights Issue Oversubscribed
In a pressrelease distributed April 12, 2018 Intervacc presented information about the outcome of the preferential share issue of Intervacc AB (publ) (“Intervacc” or “Company”) that was announced on February 18, 2018. The rights issue was subscribed to 100.5 percent with and without subscription rights. The outcome means that the rights issue was surrendered and submitted guarantee commitments do not need to be claimed. The company will receive approximately SEK 61.3 million before deduction of issue costs.
Among the additional major shareholders are Thomas Eklund (Chairman of Moberg Pharma AB and Sedana Medical as well as Board member of Boule Diagnostics AB and Biotage AB), Newton Aguiar (former Board member of Nycomed SICAR S.C.A and Phadia Group), Wilhelm Risberg and Fredrik Lundgren.
The proceeds are partially intended to be used to transfer the manufacturing technology of Strangvac® and produce two commercial batches of Strangvac® each with 30,000 doses. In this production, vaccine substance corresponding to approximately 3 – 5 million doses are produced. Strangvac® is Intervaccs first vaccine candidate, against the highly contagious equine disease strangles.